ERBB2 and breast cancer: Studies have found that 15%–50% of hormone receptor-positive, HER2-negative metastatic BC patients receive chemotherapy as first-line therapy.365 Therefore, optimizing patient survival and quality of life by selecting the most beneficial treatment modality as the primary approach is crucial.